Philip Greenberg
Medical Oncology · Seattle, WANPI 1801971635
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,530 of the $64,722 with a category attached, or 90.4%. Bristol Myers Squibb accounts for 86.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $56,250 and has fallen 97.4% since, to $1,473 in 2025.
Across 9 payments — averaging $7191.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$56K
- AbbVie$6K
- Genentech USA, Inc.$3K
Across 1 payment — averaging $1,102,096 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1.1M
What the payments were for
- Consulting fees$58,53090%
- Travel & lodging$3060%
- Food & beverage$760%
- Other$5,8109%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 3 | $56,250 |
| AbbVie | 3 | $5,810 |
| Genentech USA, Inc. | 3 | $2,662 |
How this compares
$64,722 in reported general payments places this provider in the 85th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Laura ChowSeattle$114K
- Shailender BhatiaSeattle$107K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.